Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma
- 1 July 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 116, 56-66
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research (NIHR)
- Imperial NIHR Biomedical Research Centre (BRC)
- Academy of Medical Sciences (AMS (SGL013/1021)
- The Wellcome Trust
- Medical Research Council
- British Heart Foundation
- Arthritis Research UK
- the Royal College of Physicians and Diabetes UK
This publication has 24 references indexed in Scilit:
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- Circulating Tumor Cells and Circulating Tumor DNAAnnual Review of Medicine, 2012
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomasOncogene, 2006
- Effects of Prolonged Storage of Whole Plasma or Isolated Plasma DNA on the Results of Circulating DNA Quantification AssaysJNCI: Journal of the National Cancer Institute, 2005
- Classification and prediction of survival in hepatocellular carcinoma by gene expression profilingHepatology, 2004
- Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomasOncogene, 2002